Qtern: DPP ‐4 and SGLT2 inhibitor combination for type 2 diabetes
This article discusses its indications, place in therapy and clinical trial efficacy.
Source: Prescriber - Category: Primary Care Authors: Steve Chaplin Tags: New Products Source Type: research
More News: Clinical Trials | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | SGLT2 Inhibitors